Gitterman Wealth Management LLC increased its position in shares of Danaher Co. (NYSE:DHR – Free Report) by 25.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 961 shares of the conglomerate’s stock after acquiring an additional 196 shares during the period. Gitterman Wealth Management LLC’s holdings in Danaher were worth $221,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently bought and sold shares of DHR. Envestnet Portfolio Solutions Inc. lifted its position in shares of Danaher by 11.9% during the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 84,054 shares of the conglomerate’s stock worth $19,295,000 after purchasing an additional 8,956 shares in the last quarter. one8zero8 LLC acquired a new stake in Danaher during the 4th quarter worth approximately $4,197,000. Choate Investment Advisors boosted its position in Danaher by 6.3% in the 4th quarter. Choate Investment Advisors now owns 50,143 shares of the conglomerate’s stock valued at $11,510,000 after buying an additional 2,986 shares during the period. Harrington Investments INC grew its stake in shares of Danaher by 9.4% in the fourth quarter. Harrington Investments INC now owns 1,151 shares of the conglomerate’s stock worth $264,000 after acquiring an additional 99 shares in the last quarter. Finally, Clearstead Trust LLC increased its position in shares of Danaher by 48.1% during the fourth quarter. Clearstead Trust LLC now owns 4,551 shares of the conglomerate’s stock worth $1,045,000 after acquiring an additional 1,479 shares during the period. 79.05% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling at Danaher
In related news, SVP Brian W. Ellis sold 5,700 shares of the stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at $4,534,149.90. This trade represents a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 11.10% of the company’s stock.
Wall Street Analyst Weigh In
View Our Latest Analysis on DHR
Danaher Price Performance
DHR stock opened at $211.09 on Friday. The business has a 50 day simple moving average of $220.07 and a 200-day simple moving average of $240.63. The company has a market capitalization of $150.87 billion, a P/E ratio of 39.98, a PEG ratio of 2.66 and a beta of 0.82. Danaher Co. has a twelve month low of $196.80 and a twelve month high of $281.70. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31.
Danaher (NYSE:DHR – Get Free Report) last issued its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, hitting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter in the prior year, the company posted $2.09 EPS. As a group, equities analysts anticipate that Danaher Co. will post 7.63 EPS for the current year.
Danaher Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.61%. This is a boost from Danaher’s previous quarterly dividend of $0.27. The ex-dividend date is Friday, March 28th. Danaher’s dividend payout ratio (DPR) is presently 24.24%.
Danaher Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Featured Articles
- Five stocks we like better than Danaher
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- About the Markup Calculator
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Consumer Discretionary Stocks Explained
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.